Xencor (NASDAQ:XNCR) was upgraded by research analysts at ValuEngine from a “buy” rating to a “strong-buy” rating in a report issued on Friday, ValuEngine reports.
Several other research analysts have also weighed in on XNCR. Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. Leerink Swann cut their target price on Xencor from $52.00 to $44.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. Guggenheim assumed coverage on Xencor in a research report on Wednesday, November 20th. They issued a “hold” rating on the stock. BidaskClub raised Xencor from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 7th. Finally, Mizuho reissued a “buy” rating on shares of Xencor in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $43.90.
Shares of XNCR opened at $37.36 on Friday. The company has a current ratio of 8.92, a quick ratio of 8.92 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $2.13 billion, a P/E ratio of 64.65 and a beta of 1.38. The stock’s fifty day simple moving average is $37.00 and its 200 day simple moving average is $37.48. Xencor has a twelve month low of $27.75 and a twelve month high of $46.33.
Xencor (NASDAQ:XNCR) last issued its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.40. The business had revenue of $21.76 million for the quarter, compared to analyst estimates of $4.62 million. Xencor had a return on equity of 5.84% and a net margin of 21.60%. Sell-side analysts predict that Xencor will post 0.5 earnings per share for the current year.
In other Xencor news, major shareholder John S. Stafford III sold 37,951 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $38.68, for a total value of $1,467,944.68. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder John S. Stafford III sold 120,324 shares of the firm’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $41.64, for a total value of $5,010,291.36. The disclosure for this sale can be found here. Company insiders own 4.33% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in XNCR. First Trust Advisors LP lifted its position in Xencor by 185.4% during the first quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock worth $2,167,000 after buying an additional 45,331 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its position in Xencor by 64.6% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 26,809 shares of the biopharmaceutical company’s stock worth $1,097,000 after buying an additional 10,520 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Xencor by 42.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,911 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 1,160 shares in the last quarter. Aperio Group LLC purchased a new position in Xencor during the second quarter worth approximately $152,000. Finally, DekaBank Deutsche Girozentrale lifted its position in Xencor by 63.7% during the second quarter. DekaBank Deutsche Girozentrale now owns 29,800 shares of the biopharmaceutical company’s stock worth $1,207,000 after buying an additional 11,600 shares in the last quarter. 92.43% of the stock is currently owned by institutional investors.
About Xencor
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: Bond
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Xencor Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Xencor and related companies with MarketBeat.com’s FREE daily email newsletter.
